Ten stocks kicked off the trading week soaring—seven of which soared to new 52-week highs as investors began cheering and positioning portfolios ahead of a highly anticipated interest rate cut.

The stocks outperformed Wall Street’s main indices, which all finished in the red during the session. The tech-heavy Nasdaq fell by 0.82 percent, the S&P 500 declined by 0.69 percent, while the Dow Jones was down by 0.55 percent. In this article, we name Tuesday’s 10 best-performing stocks and break down the reasons behind their strong performance.

To come up with the list, we considered the stocks with at least $2 billion in market capitalization and 5 million shares in trading volume.

10. First Majestic Silver Corp. (NYSE:AG)

Shares of First Majestic soared to a new all-time high on Tuesday, mirroring the spot prices of silver, as investors positioned ahead of a highly anticipated interest rate cut this month.

At intra-day trading, the stock climbed to its highest price of $9.62 before closing at $9.61, up 5.14 percent, closely tracking silver spot prices, which jumped by 0.46 percent to $40.88—its highest in 14 years—on optimism that lower rates would spark buying appetite for precious metals.

The Federal Reserve is set to decide on interest rates at its upcoming FOMC meeting in the next few days, with investors and analysts highly expecting a rate cut following signals from its chairman, Jerome Powell, that the central bank may finally cut rates. Any cut could weaken the US dollar and make it easier for overseas buyers to purchase precious metals such as silver and gold.

The bullish sentiment spilled over to mining stocks, including First Majestic Silver Corp. (NYSE:AG)—a company heavily focused on silver production.

In other news, First Majestic Silver Corp. (NYSE:AG) recently announced positive drilling results from its ongoing exploration program at the San Dimas Silver/Gold mine in Durango, Mexico.

“We are realizing strong results from numerous veins at San Dimas near-mine extensions at Elia, Sinaloa, Roberta, and Santa Teresa, and we are excited by the new high-grade silver and gold intercept of the Coronado vein in the West Block,” said First Majestic Silver Corp. (NYSE:AG) President and CEO Keith Neumeyer.

“These new results confirm our view that San Dimas has significant growth opportunities and remains a cornerstone asset for our long-term growth strategy,” he added.

9. Cipher Mining Inc. (NASDAQ:CIFR)

Cipher Mining soared to an all-time high anew on Tuesday, as investors loaded positions following Bitcoin’s rally during the day.

At intra-day trading, Cipher Mining Inc.’s (NASDAQ:CIFR) stock touched a new 52-week high of $8.78, before trimming gains to end the day just up by 8.9 percent at $8.32 apiece.

The rally mimicked the surge in Bitcoin prices, which, as of this writing, was up by 1.95 percent at $111,369.20.

Year-to-date, shares of Cipher Mining Inc. (NASDAQ:CIFR) have already jumped by 89 percent, fueled by the growing investor interest in cryptocurrencies.

While not directly tied to Cipher Mining Inc. (NASDAQ:CIFR), optimism was further spurred by news that President Donald Trump’s sons recently formed a new Bitcoin mining company to position themselves in the booming digital asset space.

In recent news, Cipher Mining Inc. (NASDAQ:CIFR) earned a “buy” recommendation from investment firm Canaccord with a higher price target of $9. Even with the week-on-week jump, the new price target still marked a 17.8-percent upside from Friday’s closing price.

8. Equinox Gold Corp. (NYSEAmerican:EQX)

Equinox Gold surged to a new 52-week high on Tuesday, alongside the spot prices of gold, as investors positioned ahead of an expected rate cut that could spark buying appetite for precious metals.

During the session, Equinox Gold Corp. (NYSEAmerican:EQX) touched a new record high of $9.20 before trimming gains to close up 4.34 percent at $9.14 apiece.

Meanwhile, spot prices of gold jumped by 1.8 percent during the day to touch $3,540, with investors beginning to load up positions in precious metals ahead of a widely expected rate cut. For precious metals, a lower interest rate could weaken the US dollar, making them cheaper to foreign traders.

In other news, Equinox Gold Corp. (NYSEAmerican:EQX) announced last week that it officially kicked off ore processing of one of its largest gold mine sites in Canada.

According to the company, it began processing ore at its Valentine Gold Mine in Newfoundland and Labrador—a new site with the capability of producing 2.5 million tons of gold annually.

Equinox Gold Corp. (NYSEAmerican:EQX) said it expects to pour the first batch of gold by next month.

Upon full operations, the Valentine Gold Mine is targeted to produce between 175,000 and 200,000 ounces of gold annually over the first 12 years of its 14-year reserve life.

7. QXO, Inc. (NYSE:QXO)

QXO Inc. bounced back by 4.97 percent on Tuesday to close at $21.13 apiece as investors cheered an investment firm’s bullish rating and higher price target on expectations that it could grow into a $50-billion revenue company.

In a market note, Morgan Stanley assigned an “overweight” rating and a price target of $35 on shares of QXO, Inc. (NYSE:QXO), saying that the latter, as an emerging building products distributor, could bolster its way beyond $50 billion in terms of revenues amid rosy prospects for the US industrial distribution sector, thanks to a highly fragmented industry where no player has a dominant market share.

According to Morgan Stanley, the industrial distribution sector is a highly fragmented industry where no player currently holds a significant market share. With many small players incapable of investing in technology-driven solutions, this could spark opportunities for larger players such as QXO, Inc. (NYSE:QXO) to scale up and become more efficient.

“Investments in efficiency not only lower the distributor’s cost to serve but these solutions also improve customer profitability which then pushes more wallet share back to said distributor—this is the flywheel,” it said.

In other developments, QXO, Inc. (NYSE:QXO) could also benefit from a widely expected interest rate cut by making loans for home-buying much cheaper.

6. Air Lease Corp. (NYSE:AL)

Air Lease soared to a new all-time high on Tuesday, as investors gobbled up shares following news that it was set to be acquired by an Ireland-based company for a total of $28.2 billion.

At intra-day trading, Air Lease Corp. (NYSE:AL) rallied to as high as $64.30 before paring gains to end the day just up by 6.76 percent at $64.28 apiece.

This followed news that it signed a definitive agreement with a new Ireland-based holding company for the sale of its outstanding and issued shares. The acquiring company is jointly owned by Japan-based conglomerate Sumitomo Corp., as well as SMBC Aviation Capital Ltd., and investment vehicles affiliated with Apollo and Brookfield.

Under the terms, each shareholder holding each Class A common share will be able to receive $65 in cash payment, marking a 7-percent premium over the company’s closing price of $60.66 on August 28, 2025; a 14-percent premium over the volume weighted average price (VWAP) during the 30-day period ending August 29; and 31 percent over the VWAP over the last 12 months.

The total, $28.2 billion, included debt obligations to be assumed or refinanced net of cash. Excluding the latter, the acquisition price would amount to $7.4 billion.

Air Lease Corp. (NYSE:AL) said it expected to close the transaction by the first half of 2026.

5. IREN Ltd. (NASDAQ:IREN)

IREN Ltd. soared to a new record high for the third consecutive day, as investors continued to load up positions after joining Nvidia Corp.’s preferred partners list.

In intra-day trading, IREN Ltd. (NASDAQ:IREN) soared to its highest 52-week record of $29.85 before paring gains to end the day just up by 9.93 percent at $29.11 apiece.

Last week, IREN Ltd. (NASDAQ:IREN) said it was recently named a Preferred Partner by technology giant Nvidia Corp., marking a vote of confidence among investors.

Becoming part of the list could lead to the company’s greater growth visibility and higher credibility, especially with Nvidia Corp. touted as the key enabler of the booming artificial intelligence.

In other news, IREN Ltd. (NASDAQ:IREN) announced a stellar earnings performance in the second quarter of the year, having swung to a net income of $86.9 million in the full fiscal period of 2025, a reversal from the $28.9 million net loss a year earlier.

Total revenues expanded by 167.6 percent to $501 million from $187.2 million year-on-year, with Bitcoin mining contributing the largest chunk, at $484.6 million, or 163 percent higher than the $184.1 million a year ago.

Revenues from AI cloud services, on the other hand, surged by 429 percent to $16.4 million from $3.1 million in the same comparable period.

4. Sibanye Stillwater Ltd. (NYSE:SBSW)

Sibanye Stillwater extended its winning streak to a second day on Tuesday, jumping 9.38 percent to close at $8.28 apiece as investors took path from an investment firm’s higher price target for its stock.

In its market note, BMO Capital raised its price target for Sibanye Stillwater Ltd. (NYSE:SBSW) to $8.5 from $7 previously.

Additionally, Sibanye Stillwater Ltd. (NYSE:SBSW) rallied alongside its mining counterparts after gold prices soared to a new all-time high amid a widely expected rate cut that could bolster buying of precious metals.

In the first six months of the year, Sibanye Stillwater Ltd. (NYSE:SBSW) said its headline earnings expanded by 1,846 percent to $292 million from only $15 million in the same period last year.

It also narrowed its net loss by 43 percent to $211 million from $372 million year-on-year.

3. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals soared to a new all-time high on Tuesday, as investors cheered promising results from the phase 3 studies of its drug candidate for the treatment of severe hypertriglyceridemia (sHTG).

At intra-day trading, the stock climbed by as much as 36.67 percent to its highest price of $57.91, before trimming gains to end the day just up by 34.84 percent at $57.49.

In a statement, Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) said the recent studies showed its drug candidate, Olezarsen, successfully lowered blood fat by up to 72 percent, as well as pancreas attacks by 85 percent.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) enrolled a total of 1,100 patients in the studies, marking the largest pivotal program for sHTG.

“These data are groundbreaking, demonstrating that olezarsen is the first therapy for sHTG to significantly reduce acute pancreatitis events,” said Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP Sam Tsimikas.

“Despite current standard of care and lifestyle changes, people with sHTG—who could have triglyceride levels reaching into the thousands—remain vulnerable to unpredictable and life-threatening acute pancreatitis attacks. These results reinforce our confidence that olezarsen has the potential to change the sHTG treatment paradigm,” he added.

2. Cytokinetics, Inc. (NASDAQ:CYTK)

Cytokinetics snapped a two-day losing streak on Tuesday, soaring 40.45 percent to close at $49.62 apiece as investors cheered promising results from its study of Aficamten, its drug candidate for the treatment of obstructive hypertrophic cardiomyopathy (oHCM).

In its presentation to the European Society of Cardiology Congress 2025 in Madrid, Spain over the weekend, Cytokinetics, Inc. (NASDAQ:CYTK) said it found that Aficamten helped oHCM patients exercise better than those who took Metoprolol, which actually dropped exercise abilities.

“The clinical difference in the two treatments is reinforced by the effect of Aficamten on the secondary endpoints. Compared to first-line standard-of-care metoprolol, treatment with Aficamten had a larger effect on measures of symptoms, functional class, and LVOT gradients,” said Fady Malik, executive vice president for research and development at Cytokinetics, Inc. (NASDAQ:CYTK).

Aficamten is an investigational drug candidate currently being reviewed by the US Food and Drug Administration. A decision is expected by December 26, 2025.

1. Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Mineralys surged to a new all-time high on Tuesday, as investors gobbled up shares after one of its counterparts posted positive trial results for its aldosterone synthase inhibitor (ASI), with optimism spilling over to its stock.

At intra-day trading, Mineralys Therapeutics, Inc. (NASDAQ:MLYS) surged by as high as 95 percent to hit its highest 52-week price of $30.14, before paring gains to end the day just up by 86.43 percent at $28.86 apiece.

Over the weekend, AstraZeneca said that its experimental drug called Baxdrostat showed positive results for treating patients with hard-to-control high blood pressure.

During the phase 3 trial, AstraZeneca said that the drug candidate significantly dropped enrolled patients’ systolic blood pressure by 15 mmHg on average, as compared with the placebo, which lowered blood pressure by 9-10 mmHg.

The results spilled over to Mineralys Therapeutics, Inc. (NASDAQ:MLYS), which is also underway with its own study of its ASI called Lorundrostat.

In another development, Mineralys Therapeutics, Inc. (NASDAQ:MLYS) commenced on the same day a $175 million follow-on offering to raise funds for the clinical development, research and development, manufacturing, and pre-commercialization activities of Lorundrostat.

According to the company, it also granted a 30-day option to its underwriters to purchase an additional $26.25 million of its common shares at the public offering price.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.